Amanote Research
Register
Sign In
Effects of IFN- Plus Bortezomib in Bladder Cancer
Molecular Cancer Therapeutics
- United States
doi 10.1158/1535-7163.mct-08-2-cor2
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
January 27, 2009
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Effects of Hyperthermia on Bladder Cancer
BMJ
Effects of Bortezomib in Sensitizing Human Prostate Cancer Cell Lines to NK-mediated Cytotoxicity
Asian Journal of Andrology
Medicine
Urology
Combination of Bortezomib Plus Ruxolitinib in Steroid-Refractory Chronic Graft-Versus-Host Disease
Bone Marrow Transplantation
Transplantation
Hematology
Curcumin Potentiates the Apoptotic Effects of Chemotherapeutic Agents and Cytokines Through Down-Regulation of Nuclear Factor- B and Nuclear Factor- B-Regulated Gene Products in IFN- -Sensitive and IFN- -Resistant Human Bladder Cancer Cells
Molecular Cancer Therapeutics
Cancer Research
Oncology
Effects of Increased Kindlin-2 Expression in Bladder Cancer Stromal Fibroblasts
Oncotarget
Oncology
Treatment of Relapsed Extranodal Natural Killer/T-Cell Lymphoma With Bortezomib Plus Fludarabine
Molecular and Clinical Oncology
Cancer Research
Oncology
Bladder Cancer
Nature
Multidisciplinary
Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Cancer
Cancer Research
Oncology
An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
